The sad story of Vioxx, and what we should learn f...[Cleve Clin J Med. 2004] - PubMed Result

SearchDatabase nameforSearch term

Advanced Search

Your browser version may not work well with NCBI's Web applications. More information here...

Display Show

All: 1

Review: 0

Click to change filter selection through MyNCBI.

1: Cleve Clin J Med. 2004 Dec;71(12):933-4, 936, 938-9. Links

The sad story of Vioxx, and what we should learn from it.

Karha J, Topol EJ.

Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, OH 44195, USA.

PMID: 15641522 [PubMed - indexed for MEDLINE]

Related articles

The Vioxx debacle.
IEEE Eng Med Biol Mag. 2005 Mar-Apr; 24(2):106-9.

[IEEE Eng Med Biol Mag. 2005]
Evaluating drug effects in the post-Vioxx world: there must be a better way.
Circulation. 2006 May 9; 113(18):2173-6.

[Circulation. 2006]
Clinical trials in the wake of Vioxx: requiring statistically extreme evidence of benefit to ensure the safety of new drugs.
Circulation. 2006 May 9; 113(18):2253-9.

[Circulation. 2006]
ReviewEditorial overview: from Vioxx to Luckenbach: drug discovery at a crossroads.
Curr Opin Investig Drugs. 2005 Jan; 6(1):17-20.

[Curr Opin Investig Drugs. 2005]
ReviewMethodology of therapeutic trials: lessons from the late evidence of the cardiovascular toxicity of some coxibs.
Joint Bone Spine. 2005 Dec; 72(6):451-5. Epub 2005 Oct 25.

[Joint Bone Spine. 2005]
» See reviews... | » See all...

Recent Activity

Clear Turn Off Turn On

The sad story of Vioxx, and what we should learn from it.The sad story of Vioxx, and what we should learn from it.

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

Display Show